Bristol Myers Squibb Enters Worldwide Rights Agreement for PRX005, an Exciting Novel Anti-MTBR-Tau Antibody, in Collaboration with Prothena
Tuesday, July 11, 2023
Prothena Corporation plc has recently made an announcement regarding its partnership with Bristol Myers Squibb. Bristol Myers Squibb has exercised its option to obtain exclusive worldwide commercial rights for PRX005, an innovative anti-tau antibody developed by Prothena. As part of the agreement, Bristol Myers Squibb will pay Prothena $55 million.
PRX005 is specifically designed to target the microtubule binding region (MTBR) of tau, a protein associated with Alzheimer's disease. By binding to this region, PRX005 aims to treat the disease by preventing the hyperphosphorylation and aggregation of tau, which leads to the formation of neurofibrillary tangles in the brain. These tangles, along with amyloid beta plaques, are considered hallmark indicators of Alzheimer's disease.
The ongoing Phase 1 clinical trial for PRX005 includes a multiple ascending dose (MAD) portion. Bristol Myers Squibb will be responsible for providing updates on the program, including the results from the ongoing and future clinical studies related to PRX005.
PRX005 is designed to be a best-in-class anti-tau antibody, targeting both 3R and 4R tau isoforms by specifically binding to the R1, R2, and R3 repeats within the MTBR of tau. In preclinical studies, PRX005 has demonstrated superior binding affinity, the ability to intercept and block the internalization of pathogenic tau, and a reduction in downstream neurotoxicity compared to other anti-tau antibodies.